XML 34 R20.htm IDEA: XBRL DOCUMENT v3.23.2
Restructuring
3 Months Ended
Jul. 29, 2023
Restructuring and Related Activities [Abstract]  
Restructuring

Note 13. Restructuring

The Company continually monitors market factors and industry trends and takes restructuring actions to reduce overall costs and improve operational profitability as appropriate. Restructuring actions generally result in charges for employee termination benefits, plant closures, asset impairments and contract termination costs.

In the three months ended July 29, 2023, the Company made the decision to initiate the discontinuation of the Dabir business in the Medical segment. The Company is currently executing a wind down process of the Dabir business which is expected to be completed by approximately the end of fiscal 2024 in accordance with contractual and regulatory commitments. The Company recognized $0.1 million of severance costs in the three months ended July 29, 2023 in selling and administrative expenses. The Company expects to recognize an additional $0.4 million of severance costs in the second quarter of fiscal 2024. In addition, in the three months ended July 29, 2023, the Company recognized fixed asset impairment charges of $0.6 million in cost of products sold related to this restructuring action.